Ferring 
Welcome,         Profile    Billing    Logout  
 29 Products   56 Diseases   29 Products   160 Trials   7344 News 


12345678910111213...9596»
  • ||||||||||  Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
    Review, Journal:  Faecal microbiota transplantation for recurrent Clostridiodes difficile infection & its global regulatory landscape. (Pubmed Central) -  Apr 21, 2025   
    The official FMT recommendation for recurrent CDI is emphasised from the perspective of public health, with the argument that early implementation could limit antibiotic overuse and prevent antibiotic resistance. Initiatives like the Universal Stool Bank concept aim to streamline donor selection and distribution procedures to minimise operational restrictions.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., Firmagon (degarelix) / Astellas, Ferring
    Journal:  Therapeutic potential of GNRHR analogs and SRC/FAK inhibitors to counteract tumor growth and metastasis in breast cancer. (Pubmed Central) -  Apr 13, 2025   
    Combining DEGA with PP2 or FAKi enhanced tumor inhibition, improving mice survival. These findings provide valuable insights into the essential regulatory role of gonadotropins in genes involved in tumorigenic processes, highlighting the potential of GnRHR antagonists combined with Src or FAK inhibitors as a promising strategy to develop new drugs that interfere with the ability of breast tumor progression.
  • ||||||||||  Cervidil (dinoprostone) / Ferring
    Observational data, Journal:  Nulliparous Women's Experience in the Immediate Postpartum Period After Cervical Ripening According to the Method: A Prospective Observational Study. (Pubmed Central) -  Apr 12, 2025   
    A prospective observational study included 340 nulliparous women with a singleton fetus in cephalic presentation and cervical ripening at term (?37 weeks) for maternal and/or fetal disease using a cervical ripening balloon (CRB, 33.8%), dinoprostone vaginal insert (PG, 32.7%), oral misoprostol (M, 3.8%), or repeated methods (R, 29.7%)...After adjustment, maternal experience and childbirth were similar between methods used alone for cervical ripening. Nulliparous women who required repeated methods for cervical ripening at term had significantly worse experiences of ripening and childbirth in the immediate postpartum period compared to PG, CRB, or M used alone, regardless of the mode of delivery and maternal and neonatal morbidity.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Trial completion date:  High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) -  Apr 3, 2025   
    P=N/A,  N=146, Active, not recruiting, 
    This functional assay could assist in predicting the odds for response to TNFi therapy, indicating whether a given patient is likely to respond to a specific TNFi. Trial completion date: Dec 2026 --> May 2026
  • ||||||||||  Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. (Pubmed Central) -  Mar 31, 2025   
    Future directions highlight the need for biomarker-driven models to refine treatment paradigms, reduce overtreatment, and improve long-term outcomes. Continued clinical trials are essential to validate these approaches and address unmet needs in NMIBC care.
  • ||||||||||  Rekovelle (follitropin delta) / Ferring
    Trial completion date:  Real-world Evidence on Follitropin Delta Individual Dosing (clinicaltrials.gov) -  Mar 31, 2025   
    P=N/A,  N=850, Recruiting, 
    Continued clinical trials are essential to validate these approaches and address unmet needs in NMIBC care. Trial completion date: Dec 2025 --> Mar 2026
  • ||||||||||  Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
    Review, Journal:  The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection. (Pubmed Central) -  Mar 29, 2025   
    The review delves into the emerging role of live biotherapeutics, with a particular focus on fecal microbiota-based therapies. We explore their development, mechanisms of action, clinical applications and potential to revolutionize CDI management.
  • ||||||||||  methotrexate / Generic mfg., Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Certolizumab-Induced Urticarial Vasculitis: A Case Report. (Pubmed Central) -  Mar 27, 2025   
    These findings were suggested that FZXF prescription suppresses inflammation in LPS-induced pneumonia in mice via TLR4/NF-?B and COX-2/ PGE2 pathway. With the increasing use of CZ, physicians should be aware of the possibility of UV associated with CZ.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Trial completion date:  Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study) (clinicaltrials.gov) -  Mar 27, 2025   
    P4,  N=55, Active, not recruiting, 
    With the increasing use of CZ, physicians should be aware of the possibility of UV associated with CZ. Trial completion date: Sep 2024 --> Jul 2025
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Phase classification, Trial completion date:  ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer (clinicaltrials.gov) -  Mar 26, 2025   
    P2,  N=392, Recruiting, 
    The perinatal and maternal safety profiles are comparable. Phase classification: P3 --> P2 | Trial completion date: Apr 2028 --> Apr 2031
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Journal:  KNDy Neurons and the Control of the Gonadotropic Axis in the Midgestation Fetal Sheep. (Pubmed Central) -  Mar 24, 2025   
    We used immunofluorescence histochemistry to assess the effect of chemical castration with the GnRH antagonist degarelix on arcuate KNDy neurons in fetal sheep...Blocking ?-opiate receptor (KOR) with PF4455242 significantly increased LH release. These results support the hypothesis that KNDy neurons regulate GnRH and gonadotropin secretion in midgestation sheep fetuses, acting as targets for negative feedback to maintain a stable androgen environment crucial for brain masculinization.
  • ||||||||||  Journal:  Dydrogesterone is an eligible tool to suppress LH surge in assisted reproduction technologies (ART) cycles. (Pubmed Central) -  Mar 14, 2025   
    This review explores the usage of biologic DMARDs as a therapeutic approach for RA, as well as the biomarkers typically used for RA early diagnosis, prognosis prediction, and disease activity evaluation. DYG is an eligible tool for IVF/ICSI cycles intended to freeze-all and oocyte preservation, embryo banking, and preventing OHSS in patients with high AMH levels.
  • ||||||||||  THE ASSOCIATION BETWEEN VARIOUS IBD THERAPIES AND SUBSEQUENT DEVELOPMENT OF CELIAC DISEASE (Halls C-E, Lower Level - SDCC) -  Mar 8, 2025 - Abstract #DDW2025DDW_7923;    
    First line therapy for refractory celiac disease (RCD) - present in 1% of CeD patients - is use of open capsule budesonide, but consensus therapy for RCD 2 is evolving...Of the 11 patients, 5 (45.5%) were on Infliximab, 4 (36.4%) were on Vedolizumab, 1 (9%) was on Certolizumab, and 1 (9%) was on Ustekinumab...41% received Infliximab, 22% received Adalimumab, 15% received Ustekinumab 14% received Vedolizumab, and 8% received Risankizumab...Patients receiving non-biologic therapy for IBD had a higher association with developing CeD, but patients on biologic therapies did develop CeD at varying rates. This highlights the intricacies of selecting appropriate therapies for refractory cases of CeD and need for further data driven management guidelines.